Adrian W. Quartel - 29 Jan 2026 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting relationship: Chief Medical Officer
Issuer ticker: ZVRA
Reported as of: 29 Jan 2026
Net transaction value: -$40,036
SEC form: 4
Accepted by SEC: 02 Feb 2026, 17:19:13 UTC
Prior SEC filing: 27 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Adrian W. Quartel

Key filing fact

Adrian W. Quartel filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 02 Feb 2026.

Key facts

This page summarizes Adrian W. Quartel's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 02 Feb 2026, 17:19.

Change

Previous filing in this sequence was filed on 27 Mar 2025.
Current net transaction value: -$40,036.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001910132 Primary reporting owner

Quartel Adrian W

Relationship: Chief Medical Officer
Address: C/O ZEVRA THERAPEUTICS, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Adrian W. Quartel
Signature date: 02 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZVRA transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,333
Change %: +388%
Price
Shares after: 14,256
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F1

ZVRA transaction

Common Stock

Sale

Transaction value: $40,036
Shares: -4,533
Change %: -32%
Price: $8.83
Shares after: 9,723
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +37,500
Change %
Price: $0.000000
Shares after: 37,500
Date: 29 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,500
Exercise price
Footnotes: F1, F4

ZVRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +75,000
Change %
Price: $0.000000
Shares after: 75,000
Date: 29 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $8.86
Footnotes: F5

ZVRA transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -11,333
Change %: -33%
Price: $0.000000
Shares after: 22,667
Date: 30 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,333
Exercise price
Footnotes: F1, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Adoption date of referenced 10b5-1(c) plan is: 3/26/2025.

Footnote F3

This transaction was executed in multiple trades at prices ranging from $8.62 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Footnote F4

The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Footnote F5

Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Footnote F6

One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.